US 11,834,392 B2
KDM4B inhibitors for the treatment of inflammatory diseases and disorders
Patrick M. Woster, Charleston, SC (US); and Joy E. Kirkpatrick, Charleston, SC (US)
Assigned to MUSC Foundation for Research Development, Charleston, NC (US)
Appl. No. 16/956,871
Filed by MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, Charleston, SC (US)
PCT Filed Jun. 4, 2020, PCT No. PCT/US2020/036028
§ 371(c)(1), (2) Date Jun. 22, 2020,
PCT Pub. No. WO2020/247567, PCT Pub. Date Dec. 10, 2020.
Claims priority of provisional application 62/856,799, filed on Jun. 4, 2019.
Prior Publication US 2022/0119344 A1, Apr. 21, 2022
Int. Cl. C07C 235/38 (2006.01)
CPC C07C 235/38 (2013.01) 22 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
wherein:
R1 is hydrogen, lower alkyl or alkoxy;
R2 is hydrogen, lower alkyl or alkoxy;
R3 is hydrogen or —COOH;
R4 is hydrogen, halogen or —COOH
R5 is fluorine;
R6 is hydrogen, halogen or lower alkyl; and
R7 is hydrogen, halogen or lower alkyl;
with the provisos that R1 and R2 are not both H; R3 and R7 are not both H; R5, R6 and R7 are not all F, or a pharmaceutically acceptable salt thereof.